Abstract #3294
Key Messages:
- In vivo CD3-targeted Lentivectors (LV) delivery of CAR-T transgenes represents a promising CAR-T gene therapy approach (GCAR)
- CD3-directed CAR LV generate CD19 CAR-T cells in vivo, resulting in a complete depletion of hCD20+ B cells in circulation and in lymphoid organs
- This novel approach for the rapid and direct formation of CAR-T cells in vivo was demonstrated in two different humanized mouse models
- B-Cell aplasia was obtained in lymphoreplete animal models without the use of a conditioning chemotherapy regimen, consistent with our results from studies of ex vivo transduced PBMC with CD3-directed LV
